Vanda Pharmaceuticals Stock Investor Sentiment

VNDA Stock  USD 4.92  0.02  0.40%   
About 51% of Vanda Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Vanda Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Vanda Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vanda Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  

Vanda Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Vanda Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at news.google.com         
HC Wainwright maintains 20 target on Vanda Pharmaceuticals stock - Investing.com India
Google News at Macroaxis
3 days ago at news.google.com         
Positive Outlook for Vanda Pharmaceuticals FDA Acceptance and Strong Financial Position Bolster Buy ...
Google News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 7966 shares by Kevin Moran of Vanda Pharmaceuticals at 6.2573 subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
Wells Fargo Predicts Up to 440 percent Rally for These 2 Strong Buy Stocks
Yahoo News
over a week ago at finance.yahoo.com         
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business...
Yahoo News
over a week ago at thelincolnianonline.com         
Disposition of 26941 shares by Gunther Birznieks of Vanda Pharmaceuticals at 4.76 subject to Rule 16...
news
over a week ago at thelincolnianonline.com         
Insider Buying Vanda Pharmaceuticals Inc. CEO Acquires 50,200.00 in Stock
news
over a week ago at gurufocus.com         
Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.02 subject...
Gurufocus Stories at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.01 subject...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 15520 shares by Joakim Wijkstrom of Vanda Pharmaceuticals at 4.76 subject to Rule 16b...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.705 subje...
Macroaxis News
over two weeks ago at gurufocus.com         
Disposition of 26941 shares by Timothy Williams of Vanda Pharmaceuticals at 4.76 subject to Rule 16b...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Insider Buying Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Vanda Pharmaceuticals that are available to investors today. That information is available publicly through Vanda media outlets and privately through word of mouth or via Vanda internal channels. However, regardless of the origin, that massive amount of Vanda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vanda Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vanda Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vanda Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vanda Pharmaceuticals alpha.

Vanda Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 412 shares by Kevin Moran of Vanda Pharmaceuticals at 6.3 subject to Rule 16b-3
01/30/2025
2
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
02/05/2025
3
Acquisition by Timothy Williams of 125000 shares of Vanda Pharmaceuticals subject to Rule 16b-3
02/18/2025
4
Acquisition by Kevin Moran of 2000 shares of Vanda Pharmaceuticals at 4.3894 subject to Rule 16b-3
02/21/2025
5
Vanda Pharmaceuticals announces the publication of an article titled Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S
02/24/2025
6
Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.464 subject to Rule 16b-3
02/25/2025
7
Insider Buying Mihael Polymeropoulos Acquires Shares of Vanda Pharmaceuticals Inc
02/26/2025
8
Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc
02/27/2025
9
US High Growth Tech Stocks With Strong Potential
02/28/2025
10
Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.705 subject to Rule 16b-3
03/03/2025
11
Disposition of 15520 shares by Joakim Wijkstrom of Vanda Pharmaceuticals at 4.76 subject to Rule 16b-3
03/04/2025
12
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.01 subject to Rule 16b-3
03/05/2025
13
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.02 subject to Rule 16b-3
03/06/2025
14
Disposition of 7966 shares by Kevin Moran of Vanda Pharmaceuticals at 6.2573 subject to Rule 16b-3
03/17/2025
15
HC Wainwright maintains 20 target on Vanda Pharmaceuticals stock - Investing.com India
03/19/2025

Complementary Tools for Vanda Stock analysis

When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Managers
Screen money managers from public funds and ETFs managed around the world